Background/Aims: Adrenomedullin (AM) is a recently purified hypotensive peptide and its encoding gene has been sequenced from a human pheochromocytoma. High levels of AM have been shown in Addison’s disease (AD). X-linked adrenoleukodystrophy/adrenomyeloneuropathy (ALD/AMN) is a peculiar adrenal insufficiency due to an accumulation of very-long chain fatty acid in adrenal cells and it is very often associated with a devastating demyelination of the central nervous system. Methods: We studied the AM plasma levels of 22 patients with ALD/AMN (18 with hypoadrenalism, ALDa, and 4 with normal adrenal function, ALDb) and compared them with 18 males with classical AD and 16 normal male subjects. All patients with hyposurrenalism were studied before treatment with hydrocortisone. Results: Both patients with ALD/AMN and AD showed increased levels of AM and all of them showed a significant difference from the control group (p < 0.0001). The plasma renin activity was higher in all patient groups than in the control group (p <0.001 ALDa, ALDb and AD vs. control group). The aldosterone levels were higher in ALDa and ALDb groups than AD (ALDa vs. AD p < 0.01; ALDb vs. control group p < 0.05; AD vs. controls p < 0.01). ACTH plasma levels were higher in ALDa and AD than ALDb and the control group (ALDa vs. AD not significant while ALDa and AD vs. control p <0.0001). Conclusions: Our data indicate that plasma AM levels in ALDa, ALDb and AD are higher than controls. These results were previously described in untreated AD. While classical AD patients show complete adrenal insufficiency (both mineralocorticoid and glucocorticoid defects), ALD/AMN patients show a less compromised glomerular function, indicating that AM is not completely correlated with mineralocorticoid insufficiency, and that the exact mechanism responsible for the increased AM levels in ALD/AMN is still unknown.

Keywords:
Adrenomedullin, Adrenoleukodystrophy, Adrenomyeloneuropathy, Addison’s disease, Demyelination, Central nervous system
1.
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553–560.
2.
Ichiki Y, Kitamura K, Kangawa K, Kamoto M, Matsuo H, Eto T: Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:6–10.
3.
Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, Eto T: Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin. Eur J Pharmacol 1993;241:271–273.
4.
Sakata J, Shimokubo T, Kitamura K, Nakamura S, Nakagawa K, Matsuo H, Eto T: Molecular cloning and biological activities of rat adrenomedullin receptor. Biochem Biophys Res Commun 1993;195:921–927.
5.
Letizia C, Cerci S, Centanni M, De Toma G, Subioli S, Scuro L, Scavo D: Circulating levels of adrenomedullin in patients with Addison’s disease before and after corticosteroid treatment. Clin Endocrinol 1998;48:145–148.
6.
Samson WK, Murphy T, Schell DA: A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotrophin release. Endocrinology 1995;136:2349–2352.
7.
Andreis G, Neri G, Prayer-Galetti T, Rossi GP, Gottardo G, Malendowicz LK, Nussdorfer GG: Effects of adrenomedullin on the human adrenal glands: An in vitro study. J Clin Endocrinol Metab 1997;82:1167–1170.
8.
Mosser J, Douar AM, Sarde CO, Kioshis P, Feil R, Moser H, Poutska AM, Mandel JM, Aubourg P: Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporter. Nature 1993;361:726–730.
9.
Wanders RJA, van Roermund CWT, van Wijland MJA, Schutgens RBH, van der Bosch H, Tager JM: Direct evidence that the deficient oxidation of very long chain fatty acid in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Commun 1988;153:618–624.
10.
Moser HW: Komrower Lecture. Adrenoleukodystrophy: Natural history, treatment and outcome. J Inherit Metab Dis 1995;18:435–447.
11.
Cappa M, Cambiaso P, del Balzo P, Benedetti S, Borrelli P: Hormonal evaluation of adrenoleukodystrophy; in Uziel G, Wanders RJA, Cappa M (eds): Adrenoleukodystrophy and Other Peroxisomal Disorders. Amsterdam, Elsevier, 1990, pp 81–92.
12.
Blevins LS, Shankroff J, Moser HW, Ladenson PW: Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy. J Clin Endocrinol Metab 1994;78:261–265.
13.
Betterle C, Volpato M, Pedini B, Boscaro M, Tedesco F, Presotto F: The natural history of Addison disease in organ-specific autoimmune patients with adrenocortical antibodies. Immunological study; in Bhatt HR, James WHT, Besser GM, Bottazzo GF, Keen H (eds): Advances in Thomas Addison’s Disease. Bristol, Journal of Endocrinology Ltd, 1994, vol 1, pp 51–58.
14.
Cappa M, Cambiaso P, del Balzo P, Borrelli P, Bertini E, Rimoldi M, Uziel G: Adrenoleukodystrophy: Clinical and therapeutic updating; in Bhatt HR, James WHT, Besser GM, Bottazzo GF, Keen H (eds): Advances in Thomas Addison’s Disease. Bristol, Journal of Endocrinology Ltd, 1994, vol 1, pp 171–180.
15.
Di Biase A, Salvati S, Quaresima T, Pieroni F, Grisolia A, Cambiaso P, Cappa M: C24:0/C22:0 ratio in plasma sphingomyelin as a practical tool for the diagnosis of adrenoleukodystrophy and adrenomyeloneuropathy. Clin Chem Enzym Commun 1995;7:35–40.
16.
Whitcomb RW, Linhehan WM, Knazek RA: Effects of long-chain saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J Clin Invest 1988;81:185–188.
17.
Nussdorfer GG, Rossi GP, Mazzocchi G: Role of adrenomedullin and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 1997;18:1079–1089.
18.
Letizia C, Di Iorio R, De Toma G, Marinoni E, Cerci S, Celi M, Subioli S, D’Erasmo E: Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing’s syndrome due to pituitary adenoma.Metabolism 2000;49:760–763.
19.
Takahashi K, Satoh F, Sone M, Murakami O, Sasano H, Mouri T, Shibahara S: Expression of adrenomedullin mRNA in the human brain and pituitary. Peptides 1997;18:1051–1053.
20.
Parkers DG, May CN: ACTH-suppressive and vasodilatator actions of adrenomedullin in conscious sheep. J Neuroendocrinol 1995;7:923–929.
21.
Jamaguchi T, Baba K, Doi Y, Yano K: Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. Life Sci 1995;56:379–387.
22.
Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptides. Endocr Rev 2000;21:138–167.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.